BAUS: Dimethyl Sulfoxide Cocktail May Be Alternative Treatment For Interstitial Cystitis
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




BAUS: Dimethyl Sulfoxide Cocktail May Be Alternative Treatment For Interstitial Cystitis

By David Jack
Special to DG News

DUBLIN, IRELAND -- June 29, 2000 -- A new drug cocktail including dimethyl sulfoxide should be considered as an alternative to other instillation treatments for patients with interstitial cystitis whose main symptom is pain.

Interstitial cystitis (IC) is a bladder condition with symptoms such as urinary frequency, urgency and pain, and there are characteristic signs of inflammation on cystoscopy.

Bladder instillation therapy is a widely used form of treatment although the results tend to be variable.

Cathy McLean and colleagues at the Department of Urology, Gartnavel General Hospital, Glasgow, Scotland, conducted a study to evaluated a new dimethyl sulfoxide (DMSO) cocktail that has recently been introduced in their unit for the treatent of IC.

Over a 30-month period, a total of 23 patients were treated (22 of them women) with a mean age of 55 (range 17-85) years.

Instillation of 50 mL sodium bicarbonate 8.4%, 1 mL pentosan polysulfate 100 mg/mL, 0.25 mL hydrocortisone sodium phosphate 100 mg/mL, and 50 mL DMSO 50% (v/v) was administered once a week for a period of six weeks.

Patients completed a questionnaire based on International Prostate Symptom Score (IPPS) symptom and quality of life scores, as well as a visual analog pain scale during the first and sixth months of treatment.

Of the 23 patients, 17 (75 percent) responded well to treatment and the remaining six relapsed between six and 12 months. One patient stopped after two months because they had experienced no improvement in symptoms.

The visual analog pain scores were reduced by a mean of 5.0 (range 0.1 - 7.7) and the quality of life (QOL) scores improved by a mean of 3.5 (range 1 - 6). There was no significant change in the frequency and nocturia scores.

Dr. McLean and her colleagues believe that this new cocktail should be considered as an alternative to other instillation treatments for patients whose main symptom is pain rather than frequency and urgency. They are now carrying out a longer-term follow-up of these patients, she said.

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities